Innate Pharma SA reported its consolidated financial results1 for the year ending December 31, 2022.
Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update Read More »
The primary and all key secondary endpoints were met in a Phase 3 trial evaluating the investigational use of Dupixent® compared to placebo in adults currently on maximal standard-of-care inhaled therapy with uncontrolled chronic obstructive pulmonary disease and evidence of type 2 inflammation.
Valneva SE a specialty vaccine company, reported its consolidated financial results for the year ending December 31, 20224 and provided corporate updates.
Valneva Reports Full Year 2022 Results and Provides Corporate Updates Read More »
Macomics Ltd announces that it has entered into a worldwide drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer.
Regeneron Pharmaceuticals, Inc. and Sanofi announced the primary and all key secondary endpoints were met in a Phase 3 trial evaluating the investigational use of Dupixent® compared to placebo in adults currently on maximal standard-of-care inhaled therapy with uncontrolled chronic obstructive pulmonary disease and evidence of type 2 inflammation.
Basilea Pharmaceutica Ltd announced that its license partner Asahi Kasei Pharma has reported the achievement of a milestone related to the launch of Cresemba® in Japan, which triggered a CHF 5 million payment from AKP to Basilea.
Ionis announced the outcome of the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational antisense medicine for the treatment of people with superoxide dismutase 1 amyotrophic lateral sclerosis.
Transcenta Holding Limited announces the successful dosing of first patient in the U.S. Phase I Study of TST003, its first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1, for the treatment of solid tumors.
Transcenta Holding Limited announces that two preclinical studies in relation to TST003, a First-in-Class mAb Targeting GREMLIN-1, and TST010, an ADCC enhanced anti-CD25 mAb will be presented as posters at the American Association for Cancer Research Annual Meeting 2023.
Transcenta to Present Two Preclinical Studies at AACR 2023 Read More »
Biogen Inc. announced the outcome of the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.
